Posts

Mundipharma signs major agreement with Kolon Life Sciences to bring world’s first gene therapy for knee osteoarthritis to Japan

In a multi-year agreement for up to $600 million USD, Mundipharma has acquired the exclusive rights for Invossa® in Japan from Kolon Life Sciences.